The finish line for the vaccine race is just around the corner. Terry and Dr. Bob react to vaccine developments and respond to ICER’s recent attacks.
Plus, the second part of our interview with Dr. Robert Popovian gives us the latest on Operation War Speed, President Trump’s executive orders and the impact on drug costs for patients. And Kate brings us an inside look at a clinical trial from participant Ian Haydon.
Robert Popovian, PharmD.
VP of U.S. Government Relations, Pfizer Inc.
Robert Popovian is currently Vice President, U.S. Government Relations at Pfizer Inc. where he leads the advocacy function in the U.S. Robert brings over two decades of experience in numerous facets of the biopharmaceutical and health care industry with a strong track record of expertise in Health Care Policy and Economics, Government Relations, Medical Affairs, and Strategic Planning.
Robert has published and presented extensively on the impact of biopharmaceuticals and health policies on health care costs and clinical outcomes, including authorship in clinical and healthcare delivery journals, and is a published expert source in First Word, The Hill, Los Angeles Times, USA Today, Pink Sheet, Managed Healthcare Executive and Bloomberg News amongst many others.
He also writes a regularly published column in Morning Consult regarding health policy and economic issues relevant to the biopharmaceutical industry. He is a frequent speaker at healthcare policy and medical conferences on topics such as payment and delivery reform, pricing, reimbursement, biosimilars, biopharmaceutical innovation, and health economics. He currently serves on the Board of Councilors of the University of Southern California, School of Pharmacy and Board of Advisors for Capital RX.
He is one of the few researchers who has studied and published both clinical and policy related economic analysis as well as one of a handful who have studied and published empirical data regarding emerging payment models in the U.S. healthcare system and for biopharmaceutical reimbursement. He also was one of the first to secure inclusion of health outcomes data regarding labeled indication of a biopharmaceutical.
Robert completed his Doctorate in Pharmacy and Master of Science in Pharmaceutical Economics and Policy degrees at the University of Southern California with honors. He also has completed a residency in Pharmacy Practice/Adult Internal Medicine and Infectious Diseases at the Los Angeles County – University of Southern California Hospital and a fellowship in Pharmaceutical Economics and Policy at University of Southern California.
Robert is married to Maylin Megran Popovian. They have two daughters, Katrina and Natalya. They have residences both in Los Angeles, CA and Washington, DC.
Terry Wilcox, Executive Director, Patients Rising
Dr. Robert Goldberg, “Dr. Bob”, Co-Founder and Vice President of the Center for Medicine in the Public Interest.
Kate Pecora, Field Correspondent
Dr. Robert Popovian
Voices from the Pandemic: Ian Haydon
The Federal Program That Keeps Insulin Prices High by Adam J. Fein
How Lilly is Helping Discounts Reach People with Diabetes in 340 B
Contributions of Public Health, Pharmaceuticals, and Other Medical Care to US Life Expectancy Changes, 1990-2015
How ‘Emergency Use’ Can Help Roll Out a COVID Vaccine
Pfizer Opted Not to Take Fed Money to ‘Liberate Scientists from any Bureaucracy’
Terry’s Twitter Response
Patients Rising Concierge
The successful patient is one who can get what they need when they need it. We all know insurance slows us down, so why not take matters into your own hands. Our Navigator is an online tool that allows you to search a massive network of health-related resources using your zip code so you get local results. Get proactive and become a more successful patient right now at PatientsRisingConcierge.org
Have a question or comment about the show, want to suggest a show topic or share your story as a patient correspondent?
Drop us a line: email@example.com
The views and opinions expressed herein are those of the guest(s)/ author(s) and do not reflect the official policy or position of Patients Rising.